Professor Kessen Patten's laboratory in Montreal just rewrote the textbook on amyotrophic lateral sclerosis—a disease that strikes between 3,000 and 4,000 Canadians at any given moment, stealing their ability to move with a brutal efficiency that typically kills within two to five years of diagnosis. But the breakthrough emerging from the Institut national de la recherche scientifique (INRS) suggests that if we've been looking at ALS in the wrong part of the brain all along, we may finally be looking at hope.
For decades, neuroscientists focused relentlessly on motor neurons in the brain regions responsible for movement—the motor cortex and spinal cord. This makes intuitive sense: ALS visibly destroys these cells, triggering the progressive paralysis that defines the disease. Yet Patten's team, working with zebrafish models and human tissue samples, discovered something remarkable: the disease doesn't begin where we thought. Instead, early and significant changes appear in the cerebellum, a brain region associated with balance and coordination that researchers had long underestimated in ALS pathology. These changes happen long before patients feel the first symptoms of weakness.
The researchers focused on the most common genetic form of ALS, linked to the C9orf72 gene. In zebrafish models, they documented early cerebellar atrophy—a measurable shrinking caused by the loss of two crucial neuron types: Purkinje cells and granule cells. This degeneration occurred well before motor symptoms would typically surface. Using advanced single-cell gene-sequencing technology, the team identified the culprit: decreased activity of the paics gene, which produces an enzyme essential for synthesizing purines—the molecular building blocks needed to construct and repair DNA.
Without adequate purines, neurons can't repair the DNA damage that occurs naturally during daily cellular life. This damage accumulates relentlessly, overwhelming the cell's repair systems until they fail completely, leading to neuron death. It's a slow breakdown, a molecular cascade happening invisibly in the brain years before a patient notices their hands weakening or their speech slurring.
But here's where the story pivots toward possibility. Jaskaran Singh, the doctoral student leading the experimental work, and his colleagues made a discovery that electrified the field: the mechanism appears to be reversible. When researchers restored paics gene activity in experimental models, DNA damage decreased, neurons survived, and disease progression halted at the cellular level. No cure yet. No magic bullet ready for human trials. But proof—concrete, measurable proof—that restoring this single gene function can protect neurons from degeneration.
For the nearly 1,000 Canadians diagnosed with ALS each year, this work opens multiple doors simultaneously. A better understanding of where the disease actually begins could enable earlier diagnosis, catching the disease during those crucial years before motor symptoms emerge, when intervention might matter most. It repositions ALS not as an exclusively motor problem but as a system-wide neurological condition, opening entirely new avenues for therapeutic research.
"Our results show that ALS is not limited to motor regions of the brain," Patten said. "Significant changes occur elsewhere, long before symptoms appear, which profoundly changes our understanding of the disease." The study, published in Brain, represents more than a scientific correction. For families facing this diagnosis, it represents the possibility that understanding the disease's true origin might finally unlock the key to stopping it.